Ovarian Cancer Clinical Trial
Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
The objective of this study is to prove that treatment with primary cytoreductive surgery in combination with HIPEC (treatment arm) improves outcome compared to primary cytoreductive surgery without HIPEC (standard arm) with acceptable morbidity, in patients with FIGO stage III epithelial ovarian cancer who are eligible for primary cytoreductive surgery with no residual disease, or residual disease up to 2.5 mm.
candidate for primary CRS
histological or cytological proven FIGO stage III primary epithelial ovarian, fallopian tube, or extra-ovarian cancer
history of previous malignancies within 5 years prior to inclusion
FIGO stage IV disease
complete primary cytoreduction is impossible
prior treatment for the current malignancy
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 3 Locations for this study
Bologna , , Italy More Info
Amsterdam , , Netherlands
Eindhoven , , Netherlands
Enschede , , Netherlands
Groningen , , Netherlands
Leiden , , Netherlands
Maastricht , , Netherlands
Nijmegen , , Netherlands
Rotterdam , , Netherlands
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.